Replies to post #362214 on Innovation Pharmaceuticals Inc (IPIX)

[Lemoncat]

Patience Hugon. There's a reason why we're at $0.21. It is because the market feels the same as you do.

We need good COVID results and a clear path to monetization. If Leo can deliver that we will be able to shed the IPIX credibility penalty quite rapidly.

More preclinical info won't help a company that has seven phase 2 trials in the bag. Lets see what comes from the current trial.

Go IPIX!

[LitesOut]

IPIX can't release that GMU data until GMU itself releases it. Since the broad-spectrum antiviral research is being fully funded by GMU, it is their data to release. Once they release the data then IPIX is allowed to broadcast it. The SARS-COV2 research was paid for by IPIX (the $35K payment) which allows the company to release the data as it is provided to them. It basically comes down to who is funding the research. Yes, IPIX owns all rights/benefit to the outcomes of the research, but it is not the company's research to release. It's obvious that GMU wants to wait to release the antiviral research data until the virology conference in July.